Literature DB >> 10225668

Adenosine and neopterin levels in cerebrospinal fluid of patients with neurological disorders.

Y Yoshida1, F Une, Y Utatsu, M Nomoto, Y Furukawa, Y Maruyama, N Machigashira, T Matsuzaki, M Osame.   

Abstract

We determined the cerebrospinal fluid (CSF) levels of adenosine, a mediator of cerebral blood flow regulation, and neopterin, a macrophage-producing compound, in patients with neurological disorders. Compared to control subjects, the adenosine levels were significantly increased in the patients with acute-stage cerebral infarction (n=12, p<0.0001), acute meningitis (n=10, p<0.0001), or amyotrophic lateral sclerosis (ALS, n=12, p<0.05) (Mann-Whitney U-test). The neopterin levels were significantly increased in the 41 patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis (HAM/TSP, p<0.0001), acute meningitis (p<0.0001), ALS (p<0.05) (Mann-Whitney U-test), or acute-stage cerebral infarction (p<0.005, Student's t-test). In the analysis of 41 HAM/TSP patients, the neopterin levels were significantly correlated with the cell number and glucose levels in the CSF, and were a sensitive marker of inflammation. Several of the HAM/TSP patients with increased adenosine levels were probably complicated with other diseases. The increased neopterin levels in the HAM/TSP group persisted, suggesting that the mononuclear cellular infiltration remained for a long time.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10225668     DOI: 10.2169/internalmedicine.38.133

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  9 in total

Review 1.  CSF markers in amyotrophic lateral sclerosis.

Authors:  Joanna Tarasiuk; Alina Kułakowska; Wiesław Drozdowski; Johannes Kornhuber; Piotr Lewczuk
Journal:  J Neural Transm (Vienna)       Date:  2012-05-04       Impact factor: 3.575

2.  Suppression of adenosine 2a receptor (A2aR)-mediated adenosine signaling improves disease phenotypes in a mouse model of amyotrophic lateral sclerosis.

Authors:  Seng Kah Ng; Haruki Higashimori; Michaela Tolman; Yongjie Yang
Journal:  Exp Neurol       Date:  2015-03-13       Impact factor: 5.330

3.  Urinary neopterin: A novel biomarker of disease progression in amyotrophic lateral sclerosis.

Authors:  Stephanie R Shepheard; Vassilios Karnaros; Beben Benyamin; David W Schultz; Megan Dubowsky; Joanne Wuu; Tim Chataway; Andrea Malaspina; Michael Benatar; Mary-Louise Rogers
Journal:  Eur J Neurol       Date:  2022-01-11       Impact factor: 6.288

Review 4.  The Multifaceted Role of GPCRs in Amyotrophic Lateral Sclerosis: A New Therapeutic Perspective?

Authors:  Davide Bassani; Matteo Pavan; Stephanie Federico; Giampiero Spalluto; Mattia Sturlese; Stefano Moro
Journal:  Int J Mol Sci       Date:  2022-04-19       Impact factor: 6.208

5.  Clinical and laboratory features of HTLV-I asymptomatic carriers and patients with HTLV-I-associated myelopathy/tropical spastic paraparesis from the Brazilian Amazon.

Authors:  Massanobu Takatani; Myuki Esashika Crispim; Nelson Fraiji; Mariane Martins Araujo Stefani; Dagmar Kiesslich
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2017-04-03       Impact factor: 1.846

6.  Astrocyte adenosine deaminase loss increases motor neuron toxicity in amyotrophic lateral sclerosis.

Authors:  Scott P Allen; Benjamin Hall; Lydia M Castelli; Laura Francis; Ryan Woof; Alexandros P Siskos; Eirini Kouloura; Elizabeth Gray; Alexander G Thompson; Kevin Talbot; Adrian Higginbottom; Monika Myszczynska; Chloe F Allen; Matthew J Stopford; Jordan Hemingway; Claudia S Bauer; Christopher P Webster; Kurt J De Vos; Martin R Turner; Hector C Keun; Guillaume M Hautbergue; Laura Ferraiuolo; Pamela J Shaw
Journal:  Brain       Date:  2019-03-01       Impact factor: 13.501

7.  Selective vulnerability of tripartite synapses in amyotrophic lateral sclerosis.

Authors:  Matthew J Broadhead; Calum Bonthron; Julia Waddington; William V Smith; Maite F Lopez; Sarah Burley; Jessica Valli; Fei Zhu; Noboru H Komiyama; Colin Smith; Seth G N Grant; Gareth B Miles
Journal:  Acta Neuropathol       Date:  2022-03-19       Impact factor: 15.887

8.  Abnormally high levels of virus-infected IFN-gamma+ CCR4+ CD4+ CD25+ T cells in a retrovirus-associated neuroinflammatory disorder.

Authors:  Yoshihisa Yamano; Natsumi Araya; Tomoo Sato; Atae Utsunomiya; Kazuko Azakami; Daisuke Hasegawa; Toshihiko Izumi; Hidetoshi Fujita; Satoko Aratani; Naoko Yagishita; Ryoji Fujii; Kusuki Nishioka; Steven Jacobson; Toshihiro Nakajima
Journal:  PLoS One       Date:  2009-08-05       Impact factor: 3.240

Review 9.  Amyotrophic Lateral Sclerosis (ALS) and Adenosine Receptors.

Authors:  Ana M Sebastião; Nádia Rei; Joaquim A Ribeiro
Journal:  Front Pharmacol       Date:  2018-04-16       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.